Gene and viral-vector-modified cell therapies are areas of development generating tremendous excitement in the pharmaceutical industry today. The first US FDA approvals were granted in 2017 to the chimeric antigen receptor (CAR) T-cell immunotherapies Kymriah (tisagenlecleucel) from Novartis and Yescarta (axicabtagene ciloleucel) from Kite Pharma (a Gilead Company) and the adeno-associated viral vector-based gene therapy…